JW Pharma unveils Actemra

Published: 2013-01-07 06:58:00

Updated: 2013-01-07 06:58:00

JW Pharmaceutical said Thursday it has started selling Actemra (tocilizumab) here, giving patients with rheumatoid arthritis (RA) access to the new antibody medication.

Actemra is an immunosuppressive drug, mainly for the treatment of RA and systemic juvenile idiopathic arthritis, a severe for...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK